By Mill Chart
Last update: Sep 26, 2023
Our stock screener has spotted PFIZER INC (NYSE:PFE) as a good dividend stock with solid fundamentals. NYSE:PFE shows decent health and profitability. At the same time it gives a good and sustainable dividend. We'll dive into each aspect below.
ChartMill provides a Dividend Rating for every stock, ranging from 0 to 10. This rating assesses various dividend aspects, including yield, growth, and sustainability. NYSE:PFE earns a 8 out of 10:
ChartMill assigns a proprietary Health Rating to each stock. The score is computed by evaluating various liquidity and solvency ratios and ranges from 0 to 10. NYSE:PFE was assigned a score of 5 for health:
Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NYSE:PFE has achieved a 8:
Our Best Dividend screener lists more Best Dividend stocks and is updated daily.
For an up to date full fundamental analysis you can check the fundamental report of PFE
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
NYSE:PFE (11/30/2023, 6:53:54 PM)After market: 30.67 +0.2 (+0.66%)
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
The FDA has accepted Merck's (MRK) application for approval of its drug Keytruda in combination with Seagen (SGEN) and Astellas’s Padcev for the treatment of urothelial cancer.
Pfizer has been sued by Texas Attorney General Ken Paxton, who on Thursday accused the drugmaker of misrepresenting the efficacy of its widely-used COVID-19 vaccine. In a complaint filed in a Lubbock County state court, Paxton said it was misleading for Pfizer to claim its vaccine was 95% effective because it offered a "relative risk reduction" for people to who took it. Paxton said the claim was based on only two months of clinical trial data, and vaccine recipients' "absolute risk reduction" showed that the vaccine was just 0.85% effective.
The pharmaceutical giant sought to “intimidate and silence” those who questioned the product’s efficacy, the lawsuit alleges.
Buying stocks simple for their high dividend yields is risky but these are three stocks the elite love regardless.
Pfizer has been sued by Texas Attorney General Ken Paxton, who on Thursday accused the drugmaker of misrepresenting the efficacy of its widely-used COVID-19 vaccine. In a complaint filed in a Lubbock County state court, Paxton said it was misleading for Pfizer to claim its vaccine was 95% effective because it offered a "relative risk reduction" for people to who took it. Paxton said the claim was based on only two months of clinical trial data, and that the pandemic got worse even after people started taking Pfizer's vaccine.
Global Allergy Treatment Market Breakdown by Application (Hospitals, Specialty Clinics, Homecare, Others) by Type (Eye Allergy, Food Allergy, Skin Allergy, Asthma, Rhinitis, Others) by Treatment (Anti-Allergy Drugs, Immunotherapy) by Route of Administration (Oral, Inhalation, Intranasal, Others) and by Geography (North America, South America, Europe, Asia Pacific, MEA)
Texas Attorney General Ken Paxton accused Pfizer Inc. of misrepresenting the effectiveness of the company’s COVID-19 vaccine in a lawsuit filed in state court on Thursday.
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AbbVie, J&J, Eli Lilly, Pfizer are included in this Analyst Blog.
The one thing that experts, along with vaccine makers, can agree on is that low vaccination rates put people at risk of getting severe Covid infections.